AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02619032
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
Trial: NCT02619032
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
Trial: NCT03162458
Drug: Anaferon for children (liquid dosage form)
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Trial: NCT03777319
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
Trial: NCT03777319
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be prescribed for 6 months as the clinical standard of care.
Trial: NCT01238328
Drug: Conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Trial: NCT00304863
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive the additional probiotic of lactobacillus GG
Trial: NCT03813992
Drug: MED2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Product
Trial: NCT00992823
Drug: iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
Trial: NCT01622777
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg daily of oral rosuvastatin for 12 weeks
Trial: NCT01622777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
Trial: NCT03033264
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg of a Dinoprostone vaginal insert.
Trial: NCT02481310
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02481310
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02481310
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or intraventricularly
Trial: NCT02481310
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT or intraventricularly
Trial: NCT02832596
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
Trial: NCT00109291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04197986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
Trial: NCT01229761
Drug: cotrimoxazole placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
Trial: NCT04569357
Drug: Prospekta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT04569357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT00405652
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental
Trial: NCT03845959
Drug: TD0019 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
Trial: NCT03845959
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01554800
Drug: ACP-501
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose infusion
Trial: NCT02611700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg,day1,weekly,until disease progression or toxicity
Trial: NCT00435994
Drug: Inhaled primatene will be given as a breathing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
Trial: NCT03096444
Drug: Lipoderm Cream
RxNorm normalized name: Lipoderm Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
Trial: NCT03322969
Drug: XELOX/SOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receiving the original chemotherapy
Trial: NCT01752959
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1-0.3 micg/kg/min Remifentanil iv infusion
Trial: NCT02633800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match patritumab
Trial: NCT01453907
Drug: ETI-204, Anthim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously, single dose
Trial: NCT01453907
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously, single dose
Trial: NCT02447809
Drug: acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02557854
Drug: Doxorubicin HCl liposomal injection
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg IV every 4 weeks
Trial: NCT00158223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
Trial: NCT02072382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02261493
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Trial: NCT01375348
Drug: Ultiva (remifentanil) or placebo
RxNorm normalized name: remifentanil Injection [Ultiva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
Trial: NCT01413568
Drug: POL6326
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01631630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inactive tablet design to look exactly like pioglitazone
Trial: NCT01961336
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
Trial: NCT04777045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
Trial: NCT01296698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
Trial: NCT02687932
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02395042
Drug: LiRIS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Trial: NCT02395042
Drug: LiRIS Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
Trial: NCT04110860
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
Trial: NCT03064568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03965871
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DPI is to be administered via dry powder inhaler.
Trial: NCT00994981
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
Trial: NCT00628758
Drug: Symbicort TBH - Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
Trial: NCT00628758
Drug: beta-II-agonist, inhale steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
Trial: NCT03867110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03897257
Drug: UHE-103A1 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
Trial: NCT03897257
Drug: UHE-103B cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
Trial: NCT04348305
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
Trial: NCT02061202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo training inhaler with the same instructions as the experimental group.
Trial: NCT01533493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
Trial: NCT02612311
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGR-1202: Oral daily dose
Trial: NCT00686010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, 3 tablets, oral, once daily after breakfast
Trial: NCT02651220
Drug: Epiduo® Forte Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
Trial: NCT02651220
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle used as placebo
Trial: NCT00501865
Drug: GW273225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
Trial: NCT01399866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00383162
Drug: Combination Product (sumatriptan succinate / naproxen sodium)
RxNorm normalized name: naproxen sodium / sumatriptan Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
Trial: NCT00383162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT00006136
Drug: arginine butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03298009
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week intervention
Trial: NCT00796380
Drug: Xingnaojing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT03088267
Drug: Placebo extended-release oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6, 7 or 8 mL PO
Trial: NCT05261152
Drug: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
Trial: NCT03508648
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Trial: NCT01602549
Drug: GSK962040 (25 mg tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT01602549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT00003298
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
Trial: NCT00003298
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
Trial: NCT00514735
Drug: Class I or III Antiarrhythmic Medications
RxNorm normalized name: ANTIARRHYTHMICS, CLASS I AND III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
Trial: NCT00695643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g per day
Trial: NCT01570829
Drug: Dietressa
RxNorm normalized name: Malmea depressa bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT01570829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT00794885
Drug: Enalapril/folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Trial: NCT01005758
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01005758
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01005758
Drug: hydrocortisone sodium succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01005758
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01005758
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01005758
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04899453
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
Trial: NCT01407445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/ oral/ 3 times a day for 90 days
Trial: NCT00035529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
Trial: NCT00451516
Drug: Herbal medicine (St. John's wort and Kava)
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02760316
Drug: AZD9567 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: AZD9567 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: AZD9567 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: AZD9567 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: Prednisolone 20 mg
RxNorm normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: AZD9567 125 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: AZD9567 155 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: Prednisolone 5 mg
RxNorm normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Multiple doses 5 days of treatment Once daily
Trial: NCT02760316
Drug: Prednisolone 40 mg
RxNorm normalized name: prednisolone 40 MG/ML
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Multiple doses 5 days of treatment Once daily
Trial: NCT00235716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebos for dl-alpha-tocopherol and memantine.
Trial: NCT00400335
Drug: Nanomilled testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00862134
Drug: PR104
RxNorm normalized name: PR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT03184987
Drug: FF/UMEC/VI 100/62.5/25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
Trial: NCT01817959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
Trial: NCT03262441
Drug: Mycophenolate Mofetil 500Mg Tab
RxNorm normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months